BR9709354A - Farnesyl transferase protein inhibitors - Google Patents

Farnesyl transferase protein inhibitors

Info

Publication number: BR9709354A
Authority: BR; Brazil
Prior art keywords: farnesyl transferase; protein inhibitors; transferase protein; farnesyl; inhibitors
Prior art date: 1996-05-22

Application number

BR9709354A

Other languages

Portuguese (pt)

Inventor

Ellen M Dobrusin

Daniele M Leonard

Dennis Joseph Mcnamara

Annette Marian Doherty

James Stanley Kaltenbronn

Judith Sebolt-Leopold

Kevon R Shuler

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-22

Filing date

1997-04-29

Publication date

1999-08-10

1997-04-29 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

1999-08-10 Publication of BR9709354A publication Critical patent/BR9709354A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Virology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Peptides Or Proteins (AREA)

BR9709354A 1996-05-22 1997-04-29 Farnesyl transferase protein inhibitors BR9709354A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1611096P	1996-05-22	1996-05-22
US3366296P	1996-12-17	1996-12-17
PCT/US1997/006591 WO1997044350A1 (en)	1996-05-22	1997-04-29	Inhibitors of protein farnesyl transferase

Publications (1)

Publication Number	Publication Date
BR9709354A true BR9709354A (en)	1999-08-10

Family

ID=26688183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9709354A BR9709354A (en)	1996-05-22	1997-04-29	Farnesyl transferase protein inhibitors

Country Status (18)

Country	Link
EP (1)	EP0938494A1 (en)
JP (1)	JP2000511527A (en)
CN (1)	CN1219174A (en)
AU (1)	AU728477B2 (en)
BG (1)	BG102936A (en)
BR (1)	BR9709354A (en)
CA (1)	CA2253934A1 (en)
CO (1)	CO4960642A1 (en)
CZ (1)	CZ376498A3 (en)
EA (1)	EA199801031A1 (en)
EE (1)	EE9800408A (en)
GE (1)	GEP20012500B (en)
IL (1)	IL126833A0 (en)
NO (1)	NO985405L (en)
NZ (1)	NZ332712A (en)
PL (1)	PL330120A1 (en)
SK (1)	SK161098A3 (en)
WO (1)	WO1997044350A1 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5981562A (en) *	1996-01-30	1999-11-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1997027852A1 (en) *	1996-01-30	1997-08-07	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1997027854A1 (en) *	1996-01-30	1997-08-07	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6028201A (en) *	1996-01-30	2000-02-22	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5968965A (en) *	1996-01-30	1999-10-19	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US6300501B1 (en)	1996-05-22	2001-10-09	Warner-Lambert Company	Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
US6737410B1 (en)	1997-04-11	2004-05-18	Warner-Lambert Company	Inhibitors of protein farnesyl transferase
AU6877998A (en) *	1997-04-11	1998-11-11	Warner-Lambert Company	Dipeptide inhibitors of protein farnesyltransferase
US20030069231A1 (en)	1999-10-12	2003-04-10	Klaus Rudolf	Modified aminoacids, pharmaceuticals containing these compounds and method for their production
JP2002513031A (en)	1998-04-27	2002-05-08	ワーナー−ランバート・カンパニー	Glycinamide derivatives with functionalized alkyl and alkenyl side chains as farnesyltransferase inhibitors
WO2000034239A2 (en)	1998-12-08	2000-06-15	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6284755B1 (en)	1998-12-08	2001-09-04	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
US6632818B2 (en)	2000-01-12	2003-10-14	Merck & Co., Inc.	Inhibitors of prenyl-protein transferase
JP2002188646A (en) *	2000-12-20	2002-07-05	Nsk Ltd	Rolling bearing and bearing device
US7595312B2 (en)	2002-10-25	2009-09-29	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
WO2005049589A2 (en) *	2003-10-14	2005-06-02	Cadila Healthcare Limited	Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
DE102004015723A1 (en)	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
WO2006123182A2 (en)	2005-05-17	2006-11-23	Merck Sharp & Dohme Limited	Cyclohexyl sulphones for treatment of cancer
TWI387592B (en)	2005-08-30	2013-03-01	Novartis Ag	Substituted benzimidazoles and methods of their use as inhibitors of kinases associated with tumorigenesis
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
AU2007237904B2 (en)	2006-04-19	2011-03-03	Novartis Ag	6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
WO2008039327A2 (en)	2006-09-22	2008-04-03	Merck & Co., Inc.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (en)	2007-01-10	2019-04-03	MSD Italia S.r.l.	Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
AU2008221263B2 (en)	2007-03-01	2012-02-23	Novartis Ag	Pim kinase inhibitors and methods of their use
MX2009012679A (en)	2007-05-21	2009-12-11	Novartis Ag	Csf-1r inhibitors, compositions, and methods of use.
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8691825B2 (en)	2009-04-01	2014-04-08	Merck Sharp & Dohme Corp.	Inhibitors of AKT activity
EP2440058A4 (en)	2009-06-12	2012-11-21	Dana Farber Cancer Inst Inc	FOUNDED HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN102638981B (en)	2009-10-14	2015-07-22	默沙东公司	Substituted piperidines for enhancing p53 activity and uses thereof
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
AU2011227643A1 (en)	2010-03-16	2012-09-20	Dana-Farber Cancer Institute, Inc.	Indazole compounds and their uses
US8999957B2 (en)	2010-06-24	2015-04-07	Merck Sharp & Dohme Corp.	Heterocyclic compounds as ERK inhibitors
EP2601293B1 (en)	2010-08-02	2017-12-06	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012024170A2 (en)	2010-08-17	2012-02-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2608669B1 (en)	2010-08-23	2016-06-22	Merck Sharp & Dohme Corp.	NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en)	2010-09-01	2012-03-08	Schering Corporation	Indazole derivatives useful as erk inhibitors
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en)	2010-10-29	2021-01-20	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
IN2013MN02170A (en)	2011-04-21	2015-06-12	Piramal Entpr Ltd
US9023865B2 (en)	2011-10-27	2015-05-05	Merck Sharp & Dohme Corp.	Compounds that are ERK inhibitors
EP3569598A1 (en)	2011-11-17	2019-11-20	Dana Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
EP3919620A1 (en)	2012-05-02	2021-12-08	Sirna Therapeutics, Inc.	Short interfering nucleic acid (sina) compositions
RU2660429C2 (en)	2012-09-28	2018-07-06	Мерк Шарп И Доум Корп.	Novel compounds that are erk inhibitors
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
PL2925888T3 (en)	2012-11-28	2018-03-30	Merck Sharp & Dohme Corp.	Compositions and methods for treating cancer
KR102196882B1 (en)	2012-12-20	2020-12-30	머크 샤프 앤드 돔 코포레이션	Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
ES2676734T3 (en)	2013-10-18	2018-07-24	Syros Pharmaceuticals, Inc.	Heteroatomic compounds useful for the treatment of proliferative diseases
WO2015058140A1 (en)	2013-10-18	2015-04-23	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
WO2015164604A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
JO3589B1 (en)	2014-08-06	2020-07-05	Novartis Ag	Protein kinase c inhibitors and methods of their use
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (en)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	Inhibitors of cyclin-dependent kinases
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
CA2996978A1 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
JOP20190055A1 (en)	2016-09-26	2019-03-24	Merck Sharp & Dohme	Anti-cd27 antibodies
EP3525785B1 (en)	2016-10-12	2025-08-27	Merck Sharp & Dohme LLC	Kdm5 inhibitors
MX2019012233A (en)	2017-04-13	2020-01-14	Aduro Biotech Holdings Europe Bv	ANTI-SIRPA ANTIBODIES.
US10947234B2 (en)	2017-11-08	2021-03-16	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
EP3706747B1 (en)	2017-11-08	2025-09-03	Merck Sharp & Dohme LLC	Prmt5 inhibitors
WO2019148412A1 (en)	2018-02-01	2019-08-08	Merck Sharp & Dohme Corp.	Anti-pd-1/lag3 bispecific antibodies
JP7590185B2 (en)	2018-06-25	2024-11-26	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF - Patent application
EP3833668B1 (en)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Prmt5 inhibitors
MA53287A (en)	2018-08-07	2022-05-11	Merck Sharp & Dohme	PRMT5 INHIBITORS
WO2020033284A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
AU2019413694B2 (en)	2018-12-28	2025-03-20	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
US12441730B2 (en)	2019-12-17	2025-10-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
IL322769A (en)	2023-03-02	2025-10-01	Carcimun Biotech Gmbh	Means and methods for diagnosing cancer and/or an acute inflammatory disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5352705A (en) *	1992-06-26	1994-10-04	Merck & Co., Inc.	Inhibitors of farnesyl protein transferase
AU678625B2 (en) *	1993-09-30	1997-06-05	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU681454B2 (en) *	1993-11-05	1997-08-28	Warner-Lambert Company	Substituted DI- and tripeptide inhibitors of protein:farnesyl transferase
US5571792A (en) *	1994-06-30	1996-11-05	Warner-Lambert Company	Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase

1997
- 1997-04-29 NZ NZ332712A patent/NZ332712A/en unknown
- 1997-04-29 JP JP09542369A patent/JP2000511527A/en not_active Abandoned
- 1997-04-29 EE EE9800408A patent/EE9800408A/en unknown
- 1997-04-29 EP EP97922365A patent/EP0938494A1/en not_active Withdrawn
- 1997-04-29 IL IL12683397A patent/IL126833A0/en unknown
- 1997-04-29 CN CN97194835A patent/CN1219174A/en active Pending
- 1997-04-29 SK SK1610-98A patent/SK161098A3/en unknown
- 1997-04-29 WO PCT/US1997/006591 patent/WO1997044350A1/en not_active Ceased
- 1997-04-29 CA CA002253934A patent/CA2253934A1/en not_active Abandoned
- 1997-04-29 PL PL97330120A patent/PL330120A1/en unknown
- 1997-04-29 GE GEAP19974612A patent/GEP20012500B/en unknown
- 1997-04-29 CZ CZ983764A patent/CZ376498A3/en unknown
- 1997-04-29 EA EA199801031A patent/EA199801031A1/en unknown
- 1997-04-29 AU AU28058/97A patent/AU728477B2/en not_active Ceased
- 1997-04-29 BR BR9709354A patent/BR9709354A/en not_active Application Discontinuation
- 1997-05-26 CO CO97028769A patent/CO4960642A1/en unknown
1998
- 1998-11-19 BG BG102936A patent/BG102936A/en unknown
- 1998-11-20 NO NO985405A patent/NO985405L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
SK161098A3 (en)	2000-06-12
CZ376498A3 (en)	1999-02-17
BG102936A (en)	1999-09-30
JP2000511527A (en)	2000-09-05
NZ332712A (en)	2000-07-28
AU728477B2 (en)	2001-01-11
EP0938494A1 (en)	1999-09-01
PL330120A1 (en)	1999-04-26
WO1997044350A1 (en)	1997-11-27
NO985405D0 (en)	1998-11-20
EE9800408A (en)	1999-06-15
AU2805897A (en)	1997-12-09
CN1219174A (en)	1999-06-09
CO4960642A1 (en)	2000-09-25
EA199801031A1 (en)	1999-06-24
IL126833A0 (en)	1999-08-17
CA2253934A1 (en)	1997-11-27
NO985405L (en)	1999-01-19
GEP20012500B (en)	2001-07-25

Publication	Publication Date	Title
BR9707614A (en)	1999-07-27	Farnesyl protein transferase inhibitors
BR9709354A (en)	1999-08-10	Farnesyl transferase protein inhibitors
EP0944388A4 (en)	2001-08-16	FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP1011669A4 (en)	2001-09-12	FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP0891350A4 (en)	2001-01-17	FARNESYLE PROTEIN TRANSFERASE INHIBITORS
ID24076A (en)	2000-07-06	FARNESIL PROTEIN TRANSFERASE INHIBITORS
EE9700314A (en)	1998-06-15	Farnesyl protein transferase inhibitors
EP0841919A4 (en)	1999-02-24	FARNESYLE PROTEIN TRANSFERASE INHIBITORS
EP0777475A4 (en)	1997-12-03	FARNESYLE PROTEIN TRANSFERASE INHIBITORS
EP0891360A4 (en)	2002-05-15	FARNESYL PROTEIN TRANSFERASE INHIBITORS
FI951554A7 (en)	1995-10-01	Imidazole-containing farnesyl protein transferase inhibitors
EP0784473A4 (en)	1997-12-17	PROTEIN FARNESYL TRANSFERASE INHIBITORS
FI952010A0 (en)	1995-04-27	farnesyl protein transferase inhibitors
FI952011A7 (en)	1995-04-27	Farnesyl protein transferase inhibitors
EP0904080A4 (en)	2001-08-01	FARNESYLE PROTEIN TRANSFERASE INHIBITORS
DE69924876D1 (en)	2005-05-25	FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP0783305A4 (en)	1998-04-01	FARNESYLE PROTEIN TRANSFERASE INHIBITORS
EP0812203A4 (en)	1999-04-14	GERANYLGERANYLE PROTEIN TRANSFERASE INHIBITORS
ATE214367T1 (en)	2002-03-15	FARNESYL TRANSFERASE INHIBITORS
EP0891352A4 (en)	2001-08-16	FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP1035852A4 (en)	2001-09-12	FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP1035850A4 (en)	2001-09-12	FARNESYL PROTEIN TRANSFERASE INHIBITORS
EP0891353A4 (en)	2001-08-08	FARNESYLE PROTEIN TRANSFERASE INHIBITORS
EP0787123A4 (en)	1999-10-13	FARNESYLE PROTEIN TRANSFERASE INHIBITORS
NO20012961D0 (en)	2001-06-15	Tricyclic farnesyl protein transferase inhibitors

Legal Events

Date	Code	Title	Description
2006-11-28	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2007-04-27	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.PORTANTO, INDEFIRO O PRESENTE PEDIDO.